Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04908722 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,609
- Enrollment target
NCT04908722 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 1,609 participants.
The verdict
NCT04908722, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,609 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
Interventions
- BIOLOGICAL Ad26.COV2.S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,609 participants |
| Start Date | 2021-06-18 |
| Est. Completion | 2023-07-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04908722
The ClinicalTrials.gov registry entry for NCT04908722 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Vaccines & Prevention B.V., which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ad26.COV2.S is the first listed.
NCT04908722 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04908722 about?
NCT04908722 is a clinical study titled "A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults". The purpose of this study is to demonstrate non-inferiority (NI) in terms of humoral immune responses after 6 dose levels of Ad26.COV2.S.
What is the current status of trial NCT04908722?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,609 participants. The study started on 2021-06-18. Estimated completion is 2023-07-10.
What interventions are being tested in trial NCT04908722?
The interventions under investigation include: Ad26.COV2.S (BIOLOGICAL).
Who is sponsoring clinical trial NCT04908722?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.